China's Pharmaceutical Exports To India Ⅰ
Nov 11, 2022
By sorting out the United Nations statistical database 2011-2020 HS1211 categories, HS1302
The export value of similar products (see Figure 3-5) can be found that China’s export value of traditional Chinese medicine to India is basically in the
It is about 40 million U.S. dollars, of which the growth rate was the fastest in 2014, and the export exceeded 70 million U.S. dollars, the highest level in a decade; since 2014, the growth rate of export value has been basically flat and negative, and the export value has remained stable. Therefore, on the whole, the export scale of traditional Chinese medicine to India is small.

Dichencongrong Bio-Tech Company is the world's largest Cistanche Processing Factory
The products exported are mainly planted extracts, which are mainly used in the production of dietary supplements and food additives; while the export of Chinese patent medicines and health care products is very small. Analyzing the reasons, the most important thing is that it is difficult for Chinese patent medicine to match the clinical testing system of western medicine. At the same time, there are few application scenarios, and unclear drug efficacy evaluation and testing methods inhibit the increase of exports. Compared with Chinese patent medicines, the export of primary raw material products in the Chinese medicine resource industry has relatively few technical barriers to trade, so it has become the main body of Chinese medicine product exports. However, the standardization and testing system of Chinese herbal medicine cultivation is not yet perfect, and there are problems such as excessive pesticide residues and heavy metals. It also restricts the further expansion of the export scale of traditional Chinese medicine products.

Figure 3-5 2011-2020 China's export volume and growth rate of traditional Chinese medicine to India
3.3.2 The current status of China's western medicine exports to India
It is also coded by the overall United Nations statistical database in the past ten years.
The export value of HS2936-2939, HS2941, HS3001-HS3006 products (see Figure 3-6) shows that China’s export value of western medicine to India is relatively high, and since 2016
After the year, the growth rate was relatively fast and maintained stable growth. In 2020, China's export value of western medicine to India was 1.881 billion US dollars, the highest export value in history. With the impact of the new crown pneumonia epidemic on the Indian economy and pharmaceutical companies, it is expected that the demand for Chinese western medicines, especially APIs, will continue to increase in the future.

Figure 3-6 2011-2020 China’s Western Medicine Exports to India and Growth Rate

Figure 3-7 The number of newly established enterprises in China's pharmaceutical industry from 2011 to 2020
In terms of enterprise concentration, according to the annual report on the economic operation of China's pharmaceutical industry released by the China Pharmaceutical Industry Information Center, in 2018, 76% of my country's pharmaceutical companies had insufficient annual main business income.
20 million yuan, but the contribution of Baiqiang pharmaceutical companies continues to increase, and the market concentration of large-scale companies has increased significantly.
The main business income of TOP100 reached 839.55 billion yuan, with an average annual growth rate of 11.8%. There are 22 of the top 100 pharmaceutical companies whose main business income exceeds 10 billion yuan, accounting for 32.5% of the entire industry, an increase of 7.3 percentage points year-on-year; in 2020, the main business income of the top 100 enterprises was 9012.1
100 million yuan, a year-on-year decrease of 3.1%, the first decline in the past ten years, mainly due to the superimposed influence of factors such as the new crown epidemic. Under the leading role of Baiqiang pharmaceutical companies, the level of intensive operation of pharmaceutical companies has been improved, the development momentum has been more sufficient, and the industry agglomeration effect has been prominent. Although the overall main business income has declined, more than half of the top 100 companies have achieved positive growth. At the same time, as a major producer of medical supplies, China's export delivery value has increased by 42% year-on-year.

Figure 3-8 The main business income concentration of the top 100 companies from 2015 to 2019
The main business income of the pharmaceutical industry continued to increase, and the growth rate slowed down. In recent years, due to the multiple influences of industrial structure transformation and upgrading, demand-side policy adjustment and the new crown pneumonia epidemic, the growth rate of the biopharmaceutical industry's operating income has slowed down (see Figure 3-9). The growth rate in 2020 is only 4.5%, but Still 3.7 percentage points higher than the industry-wide average.
Since 2021, the epidemic situation in my country has basically been brought under control, and a considerable number of biopharmaceutical companies have experienced related business growth brought about by the impact of the epidemic. As of September 2021, the operating income of my country's biopharmaceutical manufacturing industry has increased by 24.4% over the same period in 2020.

Cistanche Processing Factory
(2) Indian pharmaceutical companies
The company has strong strength and great international influence. In terms of quantity, India has nearly 20,000 pharmaceutical companies, but the strength of Indian pharmaceutical companies is polarized. There are a large number of small workshops for the production of pharmaceuticals and drugs in India, and there are also a number of world-renowned international pharmaceutical giants, such as the famous Sun Yat-sen. Companies such as Sun Pharma, Dr Reddy's Labs, Cipla, and others are all from India. However, in general, Indian pharmaceutical companies are large in scale, and their technology and R&D capabilities are relatively strong. In recent years, with the strong support of the Indian government, Indian pharmaceutical companies have attracted nearly 2 billion US dollars in foreign direct investment, while many Pharmaceutical companies have made a lot of foreign investment and mergers and acquisitions in Europe, America, Africa and other regions. In terms of enterprise types, pharmaceutical companies in India that produce preparations account for four-fifths, becoming the mainstream of Indian pharmaceutical companies, while companies that produce APIs account for one-fifth of Indian pharmaceutical companies, with a small number.
India's generic drug strength has always been at the forefront of the world, and India's pharmaceutical giants are also world-renowned for their generic drugs. In 2019, excluding brand companies, India accounted for half of the top ten generic drug companies in the world, and a total of 5 companies were on the list, but no Chinese companies were on the list. larger gap.

Table 3-2 Ranking of global pharmaceutical companies
High investment in R&D and rapid industrial development. The R&D strength of Indian pharmaceutical companies is much higher than that of China. According to the annual report of Indian Ranbaxy Pharmaceuticals, the company's investment in research and development over the years accounted for 12% of the company's sales, while other Indian pharmaceutical companies, such as Sun Pharmaceuticals, Dr. Reddy's Laboratories and other international pharmaceutical companies, also invested in research and development. more than 10%.
Indian international pharmaceutical giants have basically gone through the transformation and upgrading from raw materials to generic drugs to innovation. In the process of continuous transformation, companies have attached great importance to R&D investment since the beginning. Compared with the world's R&D-oriented pharmaceutical companies, R&D investment It is basically around 15%, so the achievements of Indian pharmaceutical companies are inseparable from their own emphasis on R&D in the process of development. Indian pharmaceutical companies have realized the development strategy of exporting to the world from completely relying on imports at first.
3.4.2 The scale of pharmaceutical exports
(1) China's pharmaceutical exports
Before 2010, the types of pharmaceutical products and export markets exported by my country were relatively small. The export drugs were mainly APIs, and the export markets were mainly concentrated in a few key markets. Except for the problem of few export products and markets, my country's pharmaceutical products The number of patent applications is also relatively small, and the research and development capabilities are relatively weak, and there is a big gap with developed countries in Europe and the United States. With the continuous improvement of my country's economic development level, the country has become more and more aware of the importance of the pharmaceutical industry, and has successively issued a series of development plans to promote the internationalization of the pharmaceutical industry, resulting in a steady increase in export volume. China's pharmaceutical export areas are mainly dominated by the Asian market. While the traditional market maintains steady growth, the demand for Chinese pharmaceuticals in emerging markets is rapidly increasing, opening up new demand and growth points for my country's pharmaceutical export market. In terms of the export of APIs, my country’s APIs have been exported to more than 180 countries and regions in 2019, and the export markets are mainly distributed in Asia, Europe and North America, and exports to these three major markets account for nearly 90% of my country’s pharmaceutical exports. Among them, the Asian market accounted for the largest proportion. In 2019, 5.4461 million tons of APIs were exported to Asia, with an export value of 1.5917 million tons.
USD 100 million, a year-on-year increase of 15%; while 81 tons of APIs were exported to India, with an export value of 56.53
The export products are mainly penicillin, anti-infective and other drugs. In recent years, the Indian government has proposed "Made in India" to encourage enterprises to vigorously develop upstream industries and build large-scale API factories. However, with the severe impact of the new crown pneumonia epidemic on India, it is difficult for enterprises to resume work and the economy has suffered a serious blow. The dependence of Chinese APIs will not change significantly. Most of the pharmaceutical companies in India mainly produce preparation products, so the import demand for Chinese APIs will even further increase.
In terms of export of preparations, compared with APIs, the scale is smaller and the international competitiveness is weaker. In the past ten years, Chinese pharmaceutical enterprises have continuously improved their own strength, increased investment and improvement in R&D, production, management and other aspects, and actively expanded sales in overseas markets. The export of western medicine preparations has grown rapidly. Exports of preparations increased from $1.551 billion in 2010 to $4.109 billion in 2019. By the end of 2019, nearly 290 Chinese pharmaceutical companies had listed overseas pharmaceutical products.
indivual. In terms of regions where preparations are exported, emerging markets are the main ones, and exports to developed countries are mainly concentrated in the US and German markets; the exported products are mainly injections and oral preparations.

Cistanche Processing Labs
(2) India's pharmaceutical exports
India's pharmaceutical industry occupies an important position in the world's pharmaceutical industry, with a huge pharmaceutical market and strong competitiveness in the international market. In 2010, the scale of India's pharmaceutical industry reached 21 billion US dollars. By 2019, the scale of the pharmaceutical industry has grown to nearly 30 billion US dollars. The scale of the pharmaceutical industry ranks third in the world. The most prominent one is the generic drugs in India, which take the lead in the global market. Therefore, people call India "the pharmacy of the world". The scale of India's pharmaceutical exports is also very strong. The export trade of pharmaceuticals has prompted India's foreign trade to be in a state of surplus.
The increase of the Indian government's fiscal revenue, and thus occupies a pivotal position. According to statistics, India's pharmaceutical exports in 2018-2019 were $19.13 billion, with a growth rate of
10.72%, accounting for about 6% of India's total merchandise exports.

Cistanche tubulosa
Among them, the export value of prepared medicines accounts for 70% of India's pharmaceutical exports, the largest proportion; the proportion of raw materials and intermediates is relatively small, accounting for about 20% of India's pharmaceutical exports. These data further demonstrate the international competitiveness and advantages of the Indian pharmaceutical industry.
In 2019, India exported medicines to nearly 210 countries and regions, and the sales markets were all over the world. According to the data of India's foreign trade in pharmaceuticals in 2019, the regions of India's pharmaceutical exports in 2019 were mainly North America, Africa and Europe, accounting for 66% of India's pharmaceutical exports, of which the largest proportion of pharmaceutical exports to North America was 32%. Followed by Africa and Europe, accounting for 18% and 16% respectively, it can be seen that Indian medicines are mainly sold to developed countries in Europe and the United States. From the perspective of exporting countries, the United States is the largest country in India's pharmaceutical exports, occupying a far leading position, followed by the United Kingdom, South Africa, Russia, Brazil and other countries; overall, the growth rate of pharmaceutical exports to the top ten countries is relatively fast. The export advantage is obvious.
Support: wallence.suen@wecistanche.com 0015292862950






